Shanghai HeartCare Medical IPO: Valuation Insights
Our base-case DCF valuation is HK$186.51 per share, which is a 13% upside to the mid-point of the IPO price range of HK$160.00-171.00 per share.
585 Views
Heartcare (心玮医疗) IPO: Decent Upside Barring Negative Lawsuit Outcomes
We provide an update for HeartCare's book building. We think the upside is substantial barring negative outcomes from the legal proceedings with...
318 Views
Shanghai HeartCare (心玮医疗) Pre-IPO: Thoughts on Valuation
We forecast the sales of HeartCare's four key products, namely Captor, Intracranial Catheter, LAA Occluder, and embolic coil, and also provide an...
400 Views
Zylox-Tonbridge IPO: Trading Debut
Zylox-Tonbridge priced its IPO at HK$42.70 and closed 31% up at HK$55.85 in the Futu securities grey market. Our DCF sensitivity analysis shows...
451 Views
Shanghai Heartcare IPO: Strong Potential in Treating Strokes
Though company operates in a highly competitive market, the better performance of core products can act as growth catalysts, help capture more of...
532 Views